Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions, announced strong interest and engagement from orthopedic surgeons, physicians, and cartilage repair specialists at the 8th International Cartilage Regeneration & Joint Preservation Society (ICRS) Summit, held Oct. 8-10 in Porto, Portugal. The event provided a platform for the company to showcase GelrinC®, its CE Mark-approved, cell-free hydrogel implant designed to regenerate damaged knee cartilage through a single procedure lasting approximately 10 minutes. The positive reception among key opinion leaders underscores the growing recognition of GelrinC as a potential game-changer in a market that currently lacks off-the-shelf treatment options.
The significance of this announcement lies in its implications for the future of cartilage repair. In a Phase II study, GelrinC demonstrated approximately 100% greater improvement in overall Knee Injury and Osteoarthritis Outcome Score (KOOS) scores compared with historical microfracture controls at two years, with subsequent MRI analyses showing results consistent with durable, native-like cartilage regeneration. These outcomes suggest that GelrinC could offer a more effective and efficient alternative to existing procedures, which often involve more invasive techniques and longer recovery times. With approximately 470,000 cases of cartilage knee repair annually in the U.S. alone, the potential market opportunity is substantial, and Regentis is positioning itself to capture a significant share.
Regentis is actively working to translate physician interest into broader clinical adoption through its expanding European Centers of Excellence while advancing its ongoing U.S. Food and Drug Administration pivotal trial. The company’s efforts to establish a network of Centers of Excellence are critical for building clinical evidence and driving adoption among surgeons. For investors, the strong surgeon engagement at the ICRS Summit may signal accelerating momentum toward commercialization, particularly if the U.S. pivotal trial yields positive results. The ability of GelrinC to regenerate cartilage in a controlled and synchronous process, allowing surrounding cells to regenerate tissue, sets it apart from traditional treatments and could reduce the need for repeat procedures.
To view the full press release, visit https://ibn.fm/hcEu4. The latest news and updates relating to RGNT are available in the company’s newsroom at https//ibn.fm/RGNT. As a specialized communications platform, InvestorWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, delivering access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, and social media distribution via IBN to millions of social media followers.
